Rhythm Biosciences Ltd. (AU:RHY) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Rhythm Biosciences Ltd, an Australian medical diagnostics company, has announced a significant advancement with the reception of their Alpha version multiplex antibody detection kits for colorectal cancer, developed by Quansys Biosciences. These kits integrate five separate assays into a single reaction, promising to enhance reliability, reduce turnaround time, increase throughput, and lower costs. The company is moving forward with final design, clinical validation, and exploring market entry strategies for colonoscopy triage prioritization.
For further insights into AU:RHY stock, check out TipRanks’ Stock Analysis page.